Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial

IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): safety and clinical activity results from a Phase Ib study

Primary results of ALESIA: phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC)

Phase 1 extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours.

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes

Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: results from the KEYNOTE-407 East Asia subgroup

Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib

Efficacy of TAS-120, an Irreversible Fibroblast Growth Factor Receptor Inhibitor (FGFRi), in Patients With Cholangiocarcinoma and FGFR Pathway Alterations Previously Treated With Chemotherapy and Other FGFRi’s

Practice Patterns, Radiologic Tumor Response, and Deterioration of Liver Function after Transarterial Chemoembolization (TACE): Final Analysis of OPTIMIS in Korea and Other Regions

Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from the randomized Phase III MONALEESA-7 study

Efficacy and Safety of Apalutamide (APA) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN: Asian Subpopulation

Stereotactic Ablative Radiotherapy for oligometastatic cancers: Efficacy and Toxicity Results from the randomized SABR-COMET Trial

A multi-center, randomized, double-blind, parallel, two-group Phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer

Relationship of Circulating Tumor Cells to Progression-Free Survival and Tumor Response in Patients with Metastatic Nasopharyngeal Carcinoma: A Prospective Cohort Study